Medifast expects Q3 2026 revenue between $60 mln and $80 mln
Company sees Q3 2026 loss per share between $0.15 and $0.65
Medifast expects full-year 2026 revenue between $270 mln and $300 mln
Company expects full-year 2026 loss per share between $0.25 and $1.75
Medifast expects number of active earning coaches to continue to decline in 2026
Overview
US health and wellness firm's Q2 revenue fell 28% yr/yr due to fewer active coaches
Company posted Q2 net loss, reversing profit from prior year
Revenue per active coach rose 41% yr/yr as company prioritized productive coaches
Result drivers
Fewer active coaches - Co attributed revenue decline to a drop in number of active earning coaches, citing continued pressure with client acquisition and broader challenges including rapid adoption of GLP-1 medications
Higher coach productivity - Revenue per active earning coach rose 41% yr/yr, driven by greater alignment of the coach network and prioritizing productive coaches
New initiatives - Launch of Trilivy Reset product line and Medifast Metabolic Health Institute cited as steps in transformation strategy
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the food processing peer group is "buy"
Wall Street's median 12-month price target for Medifast Inc is $12.00, about 22.1% above its July 31 closing price of $9.83
MED•
